Display options
Share it on

Dig Dis Sci. 1995 Oct;40(10):2107-12. doi: 10.1007/BF02208991.

Serum levels of interferon-alpha and -gamma in acute and chronic hepatitis B virus infection.

Digestive diseases and sciences

C M Chu, I S Sheen, C T Yeh, S Y Hsieh, S L Tsai, Y F Liaw

Affiliations

  1. Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung Medical College, Taipei, Taiwan.

PMID: 7587774 DOI: 10.1007/BF02208991

Abstract

To evaluate the potential implication of in vivo interferon production in the pathogenesis of different forms of acute and chronic hepatitis B virus infection, serum levels of interferon-alpha and -gamma were measured using immunoassay techniques in 20 patients with acute hepatitis B who subsequently cleared the virus (group Ia), 8 patients with acute hepatitis B who became HBsAg carriers (group Ib), 55 patients with chronic hepatitis B (group II), and 15 healthy controls. None of the controls had interferon-alpha or -gamma detectable in serum, while 15% and 100% of group Ia patients, 25% and 100% of group Ib patients, and 22% and 15% of group II patients, had raised serum levels of interferon-alpha and -gamma, respectively. Serum interferon-gamma was detected significantly more frequently in group Ia and Ib patients than in controls and in group II patients. Among patients with acute hepatitis B, serum levels of interferon-alpha and -gamma showed no significant difference between group Ia and group Ib patients. Among patients with chronic hepatitis B, interferon-alpha was detected significantly more frequently in patients with serum HBV-DNA (31.4% or 11/35) than in those without (5% or 1/20), whereas interferon-gamma was detected significantly more frequently in patients with chronic active hepatitis (28% or 7/25) than in those with chronic persistent hepatitis (3.3% or 1/30). In conclusion, in acute hepatitis B, serum levels of interferon-alpha and -gamma did not show a significant difference between patients who subsequently cleared the virus and those who became HBsAg carriers.(ABSTRACT TRUNCATED AT 250 WORDS)

References

  1. Hepatology. 1986 Jul-Aug;6(4):645-7 - PubMed
  2. Biomed Pharmacother. 1983;37(4):176-80 - PubMed
  3. Am J Med Sci. 1975 Jul-Aug;270(1):9-16 - PubMed
  4. Hepatology. 1986 Sep-Oct;6(5):957-61 - PubMed
  5. Liver. 1985 Jun;5(3):117-22 - PubMed
  6. Lancet. 1977 Oct 29;2(8044):914-9 - PubMed
  7. J Infect Dis. 1982 Jun;145(6):837-41 - PubMed
  8. J Infect Dis. 1984 May;149(5):831 - PubMed
  9. Proc Soc Exp Biol Med. 1971 Mar;136(3):853-6 - PubMed
  10. Proc Soc Exp Biol Med. 1968 May;128(1):251-3 - PubMed
  11. Hepatology. 1985 May-Jun;5(3):431-4 - PubMed
  12. J Med Microbiol. 1968 Nov;1(2):217-9 - PubMed
  13. Hepatology. 1989 Jan;9(1):105-9 - PubMed
  14. Gastroenterology. 1990 Apr;98(4):1029-35 - PubMed
  15. Lancet. 1982 Mar 13;1(8272):592-4 - PubMed
  16. Hepatology. 1981 Sep-Oct;1(5):431-5 - PubMed
  17. Hepatology. 1985 Mar-Apr;5(2):171-4 - PubMed
  18. Clin Exp Immunol. 1981 Dec;46(3):475-83 - PubMed
  19. Am J Clin Pathol. 1991 Apr;95(4):591-6 - PubMed
  20. Lancet. 1981 Sep 5;2(8245):497-500 - PubMed
  21. Nature. 1980 Apr 17;284(5757):593-5 - PubMed
  22. Hepatology. 1988 May-Jun;8(3):712-7 - PubMed
  23. Gastroenterology. 1983 Sep;85(3):657-62 - PubMed
  24. Hepatology. 1983 Mar-Apr;3(2):267-8 - PubMed
  25. Lancet. 1960 Jul 9;2(7141):69-71 - PubMed
  26. Gastroenterology. 1983 Nov;85(5):1138-45 - PubMed
  27. Hepatology. 1989 Dec;10(6):911-5 - PubMed
  28. J Hepatol. 1991 Nov;13(3):310-7 - PubMed
  29. Hepatology. 1989 May;9(5):715-9 - PubMed
  30. Hepatology. 1986 Sep-Oct;6(5):962-5 - PubMed

Substances

MeSH terms

Publication Types